Cabazitaxel (Jevtana®)

Common name: Cabazitaxel
Brand name: Jevtana®

What is Cabazitaxel?

Cabazitaxel is a chemotherapy drug used to treat advanced (metastatic) prostate cancer when hormonal therapy is no longer able to control the cancer. Cabazitaxel, used in combination with a corticosteroid (such as prednisone or prednisolone), is often given to men after they have been treated with docetaxel, another chemotherapy drug.

How is Cabazitaxel administered?

Cabazitaxel is administered by injection.

What are possible side effects of this treatment?

Everyone responds differently to chemotherapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received cabazitaxel. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Abdominal pain
  • Anemia (low red blood cell count)
  • Bruising / bleeding    
  • Blood in urine (hematuria)
  • Constipation    
  • Diarrhea            
  • Fatigue
  • Infection
  • Kidney problems
  • Loss of appetite
  • Muscle weakness
  • Neutropenia (low white blood cell count)
  • Numbness / tingling in hands and feet

Is Cabazitaxel covered in my province or territory?   

Cabazitaxel is covered by provincial drug programs in:
  • Alberta
  • British Columbia (restricted)
  • Ontario
  • Newfoundland & Labrador
  • Nova Scotia
  • Saskatchewan
Cabazitaxel is not covered by provincial drug programs in:
  • New Brunswick
  • Prince Edward Island
  • Quebec
  • Nunavut
  • Northwest Territories
  • Yukon
Cabazitaxel may be covered by provincial drug programs after individual review in:
  • ​Manitoba​

Last Reviewed: July 2017



Subscribe to our free monthly e-newsletter!

* indicates required


PCC Spotlight
Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  

Prostate Cancer Canada and the Movember Foundation Announce $4M in Research Grants

Toronto, October 23, 2018 – Prostate Cancer Canada and the Movember Foundation today announced $4 million in funding to three Canadian researchers to predict how well prostate cancer will respond to treatment, based on men’s biological markers, specifically in their tumour cells and blood – opening a path to more personalized care with fewer side effects and a better chance of survival.

Gay and bisexual men living with prostate cancer focus of research

Vancouver, September 25, 2018 – Research funded by Prostate Cancer Canada is preparing the way to improve quality of life for men-who-have-sex-with-men (MSM)1 in the LGBTQ2+ community.

Click here for news archive